Navigation Links
At Nearly $120 Million, The Hepatitis C Drug Market in Brazil is Among the Largest Emerging Pharmaceutical Markets for the Disease
Date:12/8/2009

WALTHAM, Mass., Dec. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that at approximately $120 million, the hepatitis C virus drug market in Brazil is among the largest emerging pharmaceutical markets for the disease. In 2008, sales of hepatitis C virus drugs in Brazil amounted to about 16 percent of the U.S. hepatitis C virus drug market (in comparison, China's and India's markets amounted to less than 10 percent each of the U.S. market). Brazil's larger market size can be attributed to the country's well established public health care system that pays for the cost of drug therapy for eligible patients.

The new Emerging Markets report entitled Hepatitis C Virus in Brazil forecasts that emerging hepatitis C virus therapies in Brazil will reach combined sales of nearly $15 million by 2013. Given Brazil's low regulatory hurdles (additional domestic clinical trials are not required) and relatively sizeable target segments, at least two novel agents--telaprevir (Vertex Pharmaceuticals/Johnson & Johnson/Mitsubishi Tanabe's VX-950/MP-424) and albinterferon-alpha-2b (Novartis/Human Genome Sciences' Albuferon)--are expected to launch towards the end of the 2008-2013 forecast period.

"Emerging therapies such as telaprevir and albinterferon-alpha-2b will find a role in the hepatitis C virus drug market in Brazil as second- and third-line therapies given the drawbacks and limitations of current treatment options and physicians' enthusiasm for novel approaches," stated Kate Hohenberg, principal director of Emerging Markets at Decision Resources.

The new report contains primary research of physicians and epidemiology study in key pharmaceutical markets of Brazil--Rio de Janeiro, Sao Paulo, Brasilia and Belo Horizonte.

About Emerging Markets Reports

Decision Resources offers a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


For more information, contact:
Gisselle Morales                             Elizabeth Marshall
Decision Resources                           Decision Resources, Inc.
781-296-2691                                 781-296-2563
gmorales@dresources.com                      emarshall@dresources.com


SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. European Small-Joint Reconstructive Implant Market to Nearly Double to $360 Million By 2014
2. Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9,000 Patients Annually
3. Gaining Too Much Weight During Pregnancy Nearly Doubles Risk of Having a Heavy Baby
4. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia
5. K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers Grains
6. ACORN Continues Success in Oncology Data Warehousing With Accumulation of Nearly 50 Million Data Observations
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
9. Gene Therapy Provides Vision to People who Were Nearly Blind
10. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
11. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
Breaking Medicine News(10 mins):